Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Public ClinicalTrials.gov record NCT01037790. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT01037790
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Enrollment
- 304 participants
Conditions and interventions
Conditions
- Adenocarcinoma of the Colon
- Adenocarcinoma of the Rectum
- Adult Central Nervous System Germ Cell Tumor
- Adult Solid Tumor
- Adult Teratoma
- Benign Teratoma
- Estrogen Receptor-negative Breast Cancer
- Estrogen Receptor-positive Breast Cancer
- Familial Testicular Germ Cell Tumor
- HER2-negative Breast Cancer
- HER2-positive Breast Cancer
- Male Breast Cancer
- Ovarian Immature Teratoma
- Ovarian Mature Teratoma
- Ovarian Monodermal and Highly Specialized Teratoma
- Progesterone Receptor-negative Breast Cancer
- Progesterone Receptor-positive Breast Cancer
- Recurrent Breast Cancer
- Recurrent Colon Cancer
- Recurrent Extragonadal Germ Cell Tumor
- Recurrent Extragonadal Non-seminomatous Germ Cell Tumor
- Recurrent Extragonadal Seminoma
- Recurrent Malignant Testicular Germ Cell Tumor
- Recurrent Melanoma
- Recurrent Ovarian Germ Cell Tumor
- Recurrent Rectal Cancer
- Stage III Extragonadal Non-seminomatous Germ Cell Tumor
- Stage III Extragonadal Seminoma
- Stage III Malignant Testicular Germ Cell Tumor
- Stage III Ovarian Germ Cell Tumor
- Stage IV Breast Cancer
- Stage IV Colon Cancer
- Stage IV Extragonadal Non-seminomatous Germ Cell Tumor
- Stage IV Extragonadal Seminoma
- Stage IV Melanoma
- Stage IV Ovarian Germ Cell Tumor
- Stage IV Rectal Cancer
- Testicular Immature Teratoma
- Testicular Mature Teratoma
Interventions
- PD-0332991 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2009
- Primary completion
- Sep 30, 2019
- Completion
- Sep 30, 2019
- Last update posted
- Mar 10, 2021
2009 – 2019
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Abramson Cancer Center of The University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01037790, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 10, 2021 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01037790 live on ClinicalTrials.gov.